202 related articles for article (PubMed ID: 32860339)
21. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
Khan MA; Carter HB; Epstein JI; Miller MC; Landis P; Walsh PW; Partin AW; Veltri RW
J Urol; 2003 Dec; 170(6 Pt 1):2274-8. PubMed ID: 14634395
[TBL] [Abstract][Full Text] [Related]
22. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract][Full Text] [Related]
23. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
24. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
[TBL] [Abstract][Full Text] [Related]
25. Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4-10 ng/mL.
Zhou Y; Li Y; Li X; Jiang M
Biomed Res Int; 2017; 2017():2512536. PubMed ID: 28293631
[TBL] [Abstract][Full Text] [Related]
26. Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.
Bhindi B; Jiang H; Poyet C; Hermanns T; Hamilton RJ; Li K; Toi A; Finelli A; Zlotta AR; van der Kwast TH; Evans A; Fleshner NE; Kulkarni GS
Urol Oncol; 2017 Oct; 35(10):604.e17-604.e24. PubMed ID: 28781111
[TBL] [Abstract][Full Text] [Related]
27. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
[TBL] [Abstract][Full Text] [Related]
28. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
Palsdottir T; Nordström T; Aly M; Jäderling F; Clements M; Grönberg H; Eklund M
Eur Urol Oncol; 2019 Sep; 2(5):490-496. PubMed ID: 31412016
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
Bollito E; De Luca S; Cicilano M; Passera R; Grande S; Maccagnano C; Cappia S; Milillo A; Montorsi F; Scarpa RM; Papotti M; Randone DF
Anal Quant Cytol Histol; 2012 Apr; 34(2):96-104. PubMed ID: 22611765
[TBL] [Abstract][Full Text] [Related]
30. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
31. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
[TBL] [Abstract][Full Text] [Related]
32. Role of PSA and its indices in determining the need for repeat prostate biopsies.
Ukimura O; Durrani O; Babaian RJ
Urology; 1997 Jul; 50(1):66-72. PubMed ID: 9218021
[TBL] [Abstract][Full Text] [Related]
33. Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
He H; Osunkoya AO; Carver P; Falzarano S; Klein E; Magi-Galluzzi C; Zhou M
BJU Int; 2012 Dec; 110(11 Pt B):E751-5. PubMed ID: 23046279
[TBL] [Abstract][Full Text] [Related]
34. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
35. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
[TBL] [Abstract][Full Text] [Related]
36. Are prostate biopsies necessary for all patients 75years and older?
Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
[TBL] [Abstract][Full Text] [Related]
37. The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods.
Lopes Vendrami C; McCarthy RJ; Chatterjee A; Casalino D; Schaeffer EM; Catalona WJ; Miller FH
Urology; 2019 Jul; 129():153-159. PubMed ID: 30926382
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
Govers TM; Caba L; Resnick MJ
J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
[TBL] [Abstract][Full Text] [Related]
39. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
[TBL] [Abstract][Full Text] [Related]
40. Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.
Prabhu V; Rosenkrantz AB; Otazo R; Sodickson DK; Kang SK
J Magn Reson Imaging; 2019 May; 49(5):1400-1408. PubMed ID: 30629317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
